Interpace can now offer the new service alone or in conjunction with ThyGenX next-generation sequencing oncogene panel in New York.
The company's ThyGenX and ThyraMir tests are designed for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
The agreement, which covers Interpace's ThyGenX and ThyraMIR diagnostic tests for the diagnosis of thyroid cancer in patients with indeterminate thyroid nodules.
During the quarter, the firm secured payor coverage for its tests with UnitedHealthcare, Premera Blue Cross, and Aetna.
Interpace Diagnostics said that the test will now be covered for Cigna's roughly 15 million members nationwide.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
The test is now covered by Premera Blue Cross, a regional health plan with more than 2 million members located primarily in Washington, Oregon, and Alaska.
The company raised net proceeds of $12.2 million, which it will use for various purposes, including working capital and payment of legacy obligations.
The firm said it will use the proceeds for working capital, trade payables, payment of legacy obligations, and general corporate purposes.
The company said in an SEC document that it will offer about 6.3 million shares of its common stock. Some purchasers would also be able to buy prefunded warrants.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.